PLRX - PLIANT THERAPEUTICS, INC.
IEX Last Trade
14.01
-0.100 -0.714%
Share volume: 6,994
Last Updated: Thu 26 Dec 2024 08:29:09 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$14.11
-0.10
-0.71%
Fundamental analysis
10%
Profitability
5%
Dept financing
3%
Liquidity
75%
Performance
0%
Performance
5 Days
1.12%
1 Month
1.12%
3 Months
20.77%
6 Months
27.50%
1 Year
-27.16%
2 Year
-25.92%
Key data
Stock price
$14.01
DAY RANGE
$13.41 - $14.21
52 WEEK RANGE
$10.60 - $19.62
52 WEEK CHANGE
-$29.41
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Bernard Coulie
Region: US
Website: pliantrx.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: pliantrx.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Pliant Therapeutics, Inc. discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins.
Recent news